HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2007.074666v1 67/4/485    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Salvarani, C Articles by Boiardi, L Search for Related Content PubMed PubMed Citation Articles by Salvarani, C Articles by Boiardi, L

–463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis

¹ Unitè Operativa di Reumatologia, Arcispedale S. Maria Nuova, Viale Risorgimento n 80, Reggio Emilia, 42100, Italy
² Laboratorio di Biologia Molecolare, Arcispedale S. Maria Nuova, Viale Risorgimento n 80, Reggio Emilia, 42100, Italy
³ Unitè Operativa di Oculistica, Arcispedale S. Maria Nuova, Viale Risorgimento n 80, Reggio Emilia, 42100, Italy

Correspondence to:
Carlo Salvarani, Unitè Operativa di Reumatologia, Arcispedale S. Maria Nuova, Viale Risorgimento n 80, Reggio Emilia, 42100, Italy; salvarani.carlo{at}asmn.re.it

Objective: To investigate potential associations between–463 G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical features of giant cell arteritis (GCA).

Methods: A total of 156 patients with biopsy-proven GCA who were residents of Reggio Emilia, Italy, and 235 population-based controls from the same geographic area were genotyped for–463 G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of polymyalgia rheumatica and severe ischaemic complications (visual loss and/or cerebrovascular accidents).

Results: The distribution of the MPO-G/A genotype differed significantly between patients with GCA and the controls (p_corr = 0.003). Allele G was significantly more frequent in patients with GCA than in the controls (p_corr = 0.0002, OR 2.0, 95% CI 1.4 to 2.9). Homozygosity for the G allele was significantly more frequent in patients with GCA than in controls (p_corr = 0.0002, OR 2.2, 95% CI 1.4 to 3.4). No significant associations were found when patients with GCA with and without polymyalgia rheumatica or with and without severe ischaemic complications were compared.

Conclusions: Our findings show that the–463 G/A promoter polymorphism of the MPO gene is associated with GCA susceptibility and support a role for MPO in the pathophysiology of GCA.